MLTX BREAKING NEWS: BFA Law is Investigating MoonLake Immunotherapeutics (NASDAQ: MLTX) for Securities Fraud after Stock Drops 90% on Drug Trial Results, Investors Urged to Contact the Firm

Core Viewpoint - MoonLake Immunotherapeutics is under investigation for potential violations of federal securities laws following disappointing results from its Phase 3 VELA trials for sonelokimab, leading to a significant drop in stock price [1][3]. Company Overview - MoonLake Immunotherapeutics is a clinical stage biotechnology company focused on therapies for inflammatory skin and joint diseases [2]. Trial Results - On September 29, 2025, MoonLake reported week 16 results from the VELA Phase 3 trials, which were highly anticipated but yielded disappointing outcomes, raising concerns about the drug's regulatory approval and commercial viability [3]. Stock Market Impact - Following the announcement of the trial results, MoonLake's stock price plummeted by $55.75 per share, nearly 90%, from $61.99 on September 28, 2025, to $6.24 on September 29, 2025 [3].